Abstract: The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.

Abstract: The present invention provides a process for purifying (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran, comprising converting an amorphous (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran to a crystalline form thereof. And also, the present invention provides a novel crystalline form of (2R,3R,4S)-6-amino-4-[N-(4-chlorophenyl)-N-(1H-imidazol-2-ylmethyl)amino]-3-hydroxy-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran and processes for preparing the same.

Abstract: The present invention relates to marine medaka genes responding to the exposure of endocrine-disrupting chemicals, and a method for diagnosing an aquatic eco-system contamination using the marine medaka genes. Specifically, the method for diagnosing an aquatic eco-system contamination, according to the present invention, makes use of marine medaka genes of which the expression amount changes according to 17?-estradiol, or marine medaka genes of which the expression amount changes according to bisphenol A. Since it was verified that genes of marine medaka exposed to 17?-estradiol are changed or genes of marine medaka exposed to bisphenol A are changed, the present invention can be used in a useful manner for a microarray chip in which marine medaka genes responding to 17?-estradiol or marine medaka genes responding to bisphenol A are integrated, for a diagnosis using same, and for a method for diagnosing health or detecting stress of a marine eco-system by applying a kit having the microarray chip.

Abstract: The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.

Abstract: The present invention relates to a method for confirming the exposure on chrysene using a DNA fragment whose expression is increased or decreased specifically when it is exposed to chrysene. The method of the present invention is effective in determination of risk by chrysene and monitoring the chrysene exposure, so that it can be effectively used as a tool for examining the mechanism of chrysene induced toxicity.

Abstract: The present invention relates to a marker gene for screening a drug inducing toxicity in human and a screening method using the same. More precisely, the invention relates to a microarray on which marker genes up-or down-regulated specifically by 16 drugs inducing pulmonary toxicity, teratogenicity, nephrotoxicity, cardiotoxicity or mutation (Methotrexate, Nitrofurantoin, Amiodarone, Carbamazepine, Valproic acid, Thalidomide, Cisplatin, Gentamycin, Amphotericine, Furylfuramide, N-nitroso-N-methylurea, methylmethanesulfonate, 4-nitroquinoline-N-oxide, 2-nitrofluorene, Doxorubicin and Daunorubicin) are integrated, a kit comprising the said microarray, and a screening method of a drug inducing toxicity in human using the same.

Abstract: The present invention relates to a screening method using the genes related to teratogenicity, more precisely the genes up- or down-regulated by a drug inducing teratogenicity such as thalidomide, valproic acid, and methotrexate and a method for screening of thalidomide, valproic acid and methotrexate using the genes. The genes of the present invention is based on reactive genes selected by DNA microarray chip, so that it is very effective in risk assessment and monitoring drugs or chemicals having high risk of teratogenicity and at the same time it can be used as a tool to examine mechanism of teratogenicity.

Abstract: The present invention relates to a method for confirming the exposure on chrysene using a DNA fragment whose expression is increased or decreased specifically when it is exposed to chrysene. The method of the present invention is effective in determination of risk by chrysene and monitoring the chrysene exposure, so that it can be effectively used as a tool for examining the mechanism of chrysene induced toxicity.

Abstract: In a voice recognition automobile vehicle capable of recognizing a human voice, an apparatus and method for prevention of driving of motor vehicle under the influence of alcohol (DUI) and prevention of vehicle theft, are provided in which a voice and a voice secret code of at least one authorized driver is stored through the voice recognition apparatus by learning and then only an authorized driver who is not determined to be legally drunk and possesses the same voice and voice secret code as the stored voice and voice secret code can be allowed to start to drive the vehicle. Only an authorized driver having the same voice and voice secret code and not determined to be legally drunk can start the engine of the vehicle.

Abstract: Disclosed are pharmaceutical compositions for the treatment and prophylaxis of heart failure, thrombosis, iNOS-induced tissue injury, septicemia, and disseminated intravascular coagulation. The compositions comprise, as a pharmacologically active ingredient, the compounds represented by the following chemical formulas 1 and 2, each of them showing heart stimulating activity, hypotensive activity, inhibitory activity against platelet aggregation, and suppressive activity against iNOS expression in combination and at once.

Abstract: A sound mode switching method for multichannel selection a video tape recorder uses a first step of making judgements on the selections of a multi-voice mode setting key and a main picture switching key, a second step for deciding the sound mode and for storing the sound mode data into a memory, a third step for making a judgement on the selection of a channel for the main picture and for outputting the selected multi-voice mode signals, and a fourth step for replacing the sub-picture. A device for multichannel selection comprises a microcomputer, a multi-voice mode selecting circuit, and a multi-voice module. According to the present invention, during a multichannel selection, independent sound signals can be outputted for the respective channels under a multi-voice mode and therefore, different sound signals can be displayed and enjoyed in a unique manner depending on the contents of the pictures for the respective channels.